Evidence map›Paper›PMID 36040013›Full record

RevieweLife2022

Integrating genomic and epidemiologic data to accelerate progress toward schistosomiasis elimination.

Andrea J Lund, Kristen J Wade, Zachary L Nikolakis, Kathleen N Ivey, Blair W Perry, Hamish N C Pike, Sara H Paull, Yang Liu, Todd A Castoe, David D Pollock and 1 more

Abstract readReview
In one paragraph

Review in eLife, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Human Schistosomiasis Vaccines as Next Generation Control Tools.Tropical medicine and infectious disease · 2023
    Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Andrea J LundDepartment of Environmental and Occupational Health, Colorado School of Public Health, University of Colorado Anschutz, Aurora, United States.ORCID 0000-0003-0880-310X
Kristen J WadeDepartment of Biochemistry & Molecular Genetics, University of Colorado School of Medicine, Aurora, United States.
Zachary L NikolakisDepartment of Biology, University of Texas at Arlington, Arlington, United States.
Kathleen N IveyDepartment of Biology, University of Texas at Arlington, Arlington, United States.
Blair W PerryDepartment of Biology, University of Texas at Arlington, Arlington, United States.
Hamish N C PikeDepartment of Biochemistry & Molecular Genetics, University of Colorado School of Medicine, Aurora, United States.
Sara H PaullDepartment of Environmental and Occupational Health, Colorado School of Public Health, University of Colorado Anschutz, Aurora, United States.
Yang LiuSichuan Centers for Disease Control and Prevention, Chengdu, China.
Todd A Castoe *Department of Biology, University of Texas at Arlington, Arlington, United States.
David D Pollock *Department of Biochemistry & Molecular Genetics, University of Colorado School of Medicine, Aurora, United States.ORCID 0000-0002-7627-4214
Elizabeth J Carlton *Department of Environmental and Occupational Health, Colorado School of Public Health, University of Colorado Anschutz, Aurora, United States.ORCID 0000-0002-8664-9606

Funding

Schistosomiasis at the edge of elimination: characterizing sources of new infections in residual transmission hotspotsR01AI134673 · NIAID · UNIVERSITY OF COLORADO DENVER · PI CARLTON, ELIZABETH · 2019 to 2023
$3.5M
NIAID NIH HHS R01 AI134673
6 · The paper itself

Abstract

The global community has adopted ambitious goals to eliminate schistosomiasis as a public health problem, and new tools are needed to achieve them. Mass drug administration programs, for example, have reduced the burden of schistosomiasis, but the identification of hotspots of persistent and reemergent transmission threaten progress toward elimination and underscore the need to couple treatment with interventions that reduce transmission. Recent advances in DNA sequencing technologies make whole-genome sequencing a valuable and increasingly feasible option for population-based studies of complex parasites such as schistosomes. Here, we focus on leveraging genomic data to tailor interventions to distinct social and ecological circumstances. We consider two priority questions that can be addressed by integrating epidemiological, ecological, and genomic information: (1) how often do non-human host species contribute to human schistosome infection? and (2) what is the importance of locally acquired versus imported infections in driving transmission at different stages of elimination? These questions address processes that can undermine control programs, especially those that rely heavily on treatment with praziquantel. Until recently, these questions were difficult to answer with sufficient precision to inform public health decision-making. We review the literature related to these questions and discuss how whole-genome approaches can identify the geographic and taxonomic sources of infection, and how such information can inform context-specific efforts that advance schistosomiasis control efforts and minimize the risk of reemergence.

Indexed as

ParasitesSchistosomiasisAnimalsGenomicsMass Drug AdministrationSchistosomadisease controlepidemiologygeneticsgenomicsglobal healthone healthpopulation geneticsschistosomiasissurveillancewhole-genome sequencing

Identifiers

PMID36040013
PMCPMC9427098

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.